ribosomal protein L39 likeGenealiases: L39-2 · RPL39L1
Q-omics provides the consensus-scored RPL39L profile across patient tissues and cancer cell-line models. RPL39L expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL39L is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, RPL39L RNA expression shows 17,883 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, LUAD, and LSCC as cancer lineages where RPL39L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL39L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL39L survival associations across molecular data types. RPL39L RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL39L RNA expression–survival associations across cancer types. High RPL39L expression shows unfavorable associations in ACC, UCEC, MESO, LGG, GBM and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL39L RNA expression.
This table summarizes RPL39L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL39L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL39L shows higher tumor expression in LUAD, LUSC, HNSC, BRCA, LIHC and STAD. The LUAD box plot shows higher RPL39L RNA expression in tumor versus normal tissue (log2 FC = +2.346, t-test p < 0.001).
This table shows molecular features associated with RPL39L in patient tissues and cancer cell lines. In patient samples, RPL39L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL39L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Myeloma.
